4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

A tiny chip, smart glasses and months of training are rewriting what blindness means for older people with failing central ...

Presenters at the AAO 2025 meeting outlined a future for retinal care that reduces patient burden by reconsidering treatment delivery methods.

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

For the first time, scientists have managed to restore central vision loss from an irreversible age-related eye condition via ...